DDInter1158 DDInter921
An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease. Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent. Throughout the late seventies and the eighties, important research initiatives developed stable mesalazine formulations like the eudragit-S coating of Asacol brand mesalazine and the Pentasa brand's encapsulation of mesalazine within microgranules. In the present day, contemporary research regarding novel methods to stabilize mesalazine continues and interest in the agent's capacity to decrease inflammatory activity and subsequently potentially reduce the risk of colorectal cancer in conditions like ulcerative colitis is maintained.[A174019,A174022]
Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlorobenzoyl)25-methoxy-2-methylindole-3-acetic acid. The pharmacological effect of indometacin is not fully understood, however, it is thought to be mediated through potent and nonselective inhibition of the enzyme cyclooxygenase (COX), which is the main enzyme responsible for catalyzes the rate-limiting step in prostaglandin and thromboxane biosynthesis via the arachidonic acid (AA) pathway. Indometacin was first discovered in 1963 and it was first approved for use in the U.S. by the Food and Drug Administration in 1965, along with other acetic acid derivatives such as [diclofenac] and [sulindac] that were also developed during the 1960s. Since then, indometacin has been extensively studied in clinical trials as one of the most potent NSAIDs in blocking prostaglandin synthesis and was among the first NSAIDs to be used in the symptomatic treatment of migraine and for headaches that eventually became known as “indomethacin-responsive” headache disorders. Most commonly used in rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute shoulder pains, and acute gouty arthritis, indometacin is currently available as oral capsules as well as other methods of administration, including rectal and intravenous formulations. Intravenous indometacin is administered to close a hemodynamically significant patent ductus arteriosus, as indicated by clinical evidence, in premature infants. Ophthalmic indometacin has been studied and used in the symptomatic treatment of postoperative ocular inflammation and pain and/or complications after cataract surgery. Although deemed effective in reducing ocular inflammation in clinical studies, topical NSAIDs were also associated with a potential reduction in corneal sensitivity accompanied by an increased risk of superficial punctate keratitis and subjective symptoms of discomfort, including pain, burning or pricking, or a tingling sensation after instillation into the cul‐de‐sac.
Mesalazine {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Indomethacin
Mesalazine {u} (Compound) causes {v} (Side Effect) Sweating
Sweating {u} (Side Effect) is caused by {v} (Compound) Indomethacin
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Indomethacin
Mesalazine {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Bromfenac
Bromfenac {u} (Compound) resembles {v} (Compound) Indomethacin
Mesalazine {u} (Compound) causes {v} (Side Effect) Sweating
Sweating {u} (Side Effect) is caused by {v} (Compound) Fenofibrate
Fenofibrate {u} (Compound) resembles {v} (Compound) Indomethacin
Mesalazine {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Bezafibrate
Bezafibrate {u} (Compound) resembles {v} (Compound) Indomethacin
Mesalazine {u} (Compound) causes {v} (Side Effect) Rectal tenesmus
Rectal tenesmus {u} (Side Effect) is caused by {v} (Compound) Dipyridamole
Dipyridamole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Indomethacin
Mesalazine {u} (Compound) causes {v} (Side Effect) Bone marrow depression
Bone marrow depression {u} (Side Effect) is caused by {v} (Compound) Cimetidine
Cimetidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Indomethacin
Mesalazine {u} (Compound) resembles {v} (Compound) Carbidopa
Carbidopa {u} (Compound) causes {v} (Side Effect) Vascular purpura
Vascular purpura {u} (Side Effect) is caused by {v} (Compound) Indomethacin
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bromfenac
Bromfenac {u} (Compound) resembles {v} (Compound) Indomethacin
Mesalazine (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Indomethacin (Compound)
Mesalazine (Compound) causes Sweating (Side Effect) and Sweating (Side Effect) is caused by Indomethacin (Compound)
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin
Mesalazine (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Bromfenac (Compound) and Bromfenac (Compound) resembles Indomethacin (Compound)
Mesalazine (Compound) causes Sweating (Side Effect) and Sweating (Side Effect) is caused by Fenofibrate (Compound) and Fenofibrate (Compound) resembles Indomethacin (Compound)
Mesalazine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Bezafibrate (Compound) and Bezafibrate (Compound) resembles Indomethacin (Compound)
Mesalazine (Compound) causes Rectal tenesmus (Side Effect) and Rectal tenesmus (Side Effect) is caused by Dipyridamole (Compound) and Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin
Mesalazine (Compound) causes Bone marrow depression (Side Effect) and Bone marrow depression (Side Effect) is caused by Cimetidine (Compound) and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Indomethacin
Mesalazine (Compound) resembles Carbidopa (Compound) and Carbidopa (Compound) causes Vascular purpura (Side Effect) and Vascular purpura (Side Effect) is caused by Indomethacin (Compound)
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac and Bromfenac (Compound) resembles Indomethacin (Compound)